Thus, prostate cancer cells with PTEN mutations or deletions have elevated PI3K and AKT/PKB activation levels, which is likely to bestow survival benefits onto these cells when challenged by physiological surveillance mechanisms or treatment with chemotherapeutic agents or biologicals such as TRAIL. This evidence concerns the gene AKT1 and Familial prostate cancer.